{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:30:51Z","timestamp":1777548651748,"version":"3.51.4"},"reference-count":68,"publisher":"Informa UK Limited","issue":"35","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.2217\/fon-2021-0778","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T10:20:53Z","timestamp":1632392453000},"page":"4849-4860","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) for the Management of Relapsed Multiple Myeloma"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology,University of California San Francisco,\rSan Francisco,\rCA\r94143,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Division of Hematology\/Oncology,University of California San Francisco,\rSan Francisco,\rCA\r94143,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Thomas G","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology,University of California San Francisco,\rSan Francisco,\rCA\r94143,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3176"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17235"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000734"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_320129"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155192"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00501"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139893"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136985"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-133873"},{"key":"e_1_3_3_13_1","unstructured":"US FDA . Package insert: Abecma (idecabtagene vicleucel) (2021)."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1827253"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15680"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.04.007"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.42"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.240"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1813"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33448"},{"key":"e_1_3_3_22_1","unstructured":"US FDA . Package insert: Sarclisa\u00ae (isatuximab) (2021)."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"e_1_3_3_24_1","unstructured":"European Medicines Agency .Committee for Medicinal Products for Human Use (CHMP) Summary of Opinion: Sarclisa \/ isatuximab (2021). www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-sarclisa-ii-03_en.pdf"},{"key":"e_1_3_3_25_1","unstructured":"Sanofi . European Commission approves second indication of Sarclisa\u00ae (isatuximab) for relapsed multiple myeloma (2021)."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01187"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740787"},{"key":"e_1_3_3_33_1","volume-title":"Presented at: European Hematology Association.","author":"Usmani SZ","year":"2019","unstructured":"Usmani SZ , KaranesC, BensingerWet al. Preliminary data: Phase 1B study of feasibility\/safety of isatuximab short-duration fixed-volume infusion in combination with pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma. Presented at: European Hematology Association.Amsterdam, Netherlands (June 15, 2019). https:\/\/library.ehaweb.org\/eha\/2019\/24th\/267007\/saad.usmani.preliminary.data.phase.1b.study.of.feasibility.safety.of.html"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0198-4"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-02-895193"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0857-2"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12561"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008209"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.04.018"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0431"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129963"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247"},{"key":"e_1_3_3_46_1","volume-title":"Presented at: European Hematology Association.","author":"Moreau P","year":"2020","unstructured":"Moreau P , DimopoulosM, MikhaelJet al. LB2603: isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (IKEMA): interim analysis of a Phase 3, randomized, open-label study. Presented at: European Hematology Association. (June 14, 2020). https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/303392\/philippe.moreau.isatuximab.plus.carfilzomib.and.dexamethasone.vs.carfilzomib.html"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137681"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017005447"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8026"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-6367(21)00092-0"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136415"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0711-6"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01814"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8017"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137602"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141291"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135874"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0026-7"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017015545"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00478-4"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.1220.01071"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119589"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002958"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-0778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:06Z","timestamp":1719124986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-0778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":68,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.2217\/fon-2021-0778"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-0778","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}